Filagrastim 300 mg/0.5 ml

Product Description

Introduction to Religrast 300mcg Injection

Religrast 300mcg injection contains the active constituent filgrastim. It is a white blood cell growth factor (granulocyte-colony stimulating factor) approved by the FDA to decrease the risk of developing febrile neutropenia (occurrence of fever or infection associated with low WBC count) and to reduce the duration of neutropenia (low white blood cell count) in people who have non-myeloid cancer and are receiving chemotherapy drugs. It is also used to increase the number of WBCs and decrease the length of time of fever in people with acute myeloid leukemia. 

It is also used in people undergoing bone marrow transplants and in people with severe chronic neutropenia (low number of neutrophils in the blood). Religrast 300mcg injection is also used to prepare the blood for leukapheresis (a treatment in which certain blood cells are removed from the blood). It is also indicated to increase the chance of survival in people exposed to harmful amounts of radiation, which can cause severe damage to the bone marrow. Other uses include in patients with advanced HIV infection, which will help to reduce the risk of infections. 

Religrast 300mcg injection belongs to the class of medications called colony-stimulating factors. They work by helping the body to produce more White blood cells. WBC is important because it helps your body fight infection. These cells are highly sensitive to the effects of chemotherapy, which might cause a decrease in the number. If your WBC decreases, your body may not have enough cells to combat bacteria, putting you at risk of infection. Inform your physician if you have had liver disease, kidney problems, sickle cell anemia, or bone disease. Common side effects include fever, pain, rash, cough, shortness of breath, and nosebleeds.

Uses of Religrast 300mcg Injection

• To prevent infections after chemotherapy due to decreased white blood cells (neutropenia)